Taiji Group: Subsidiary receives approval notice for clinical trials of Simcere Glycopeptide Injection.

The announcement of Taiji Group stated that its wholly-owned subsidiary Fuling Pharmaceutical Factory received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for Semaglutide Injection, approving the clinical trial for the indication of type 2 diabetes. Semaglutide Injection is a long-acting glucagon-like peptide-1 receptor agonist, used for blood sugar control in adult type 2 diabetes patients and reducing the risk of major cardiovascular events in adult type 2 diabetes patients with concomitant cardiovascular disease. The company has accumulated approximately 44.1834 million yuan in R&D investment in this project.